These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2857291)

  • 41. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
    Fisher VL; Barnes YJ; Nuss SL
    Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Busulphan and cyclophosphamide for pretransplant conditioning.
    Shaw PJ; Stevens MM
    Bone Marrow Transplant; 1988 Jul; 3(4):367. PubMed ID: 3048500
    [No Abstract]   [Full Text] [Related]  

  • 43. High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma.
    Loiseau HA; Hartmann O; Valteau D; McDowell H; Brugières L; Vassal G; Kalifa C; Patte C; Lemerle J
    Bone Marrow Transplant; 1991 Dec; 8(6):465-72. PubMed ID: 1790426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
    Méresse V; Hartmann O; Vassal G; Benhamou E; Valteau-Couanet D; Brugieres L; Lemerle J
    Bone Marrow Transplant; 1992 Aug; 10(2):135-41. PubMed ID: 1525602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic myeloid leukaemia in Zambians.
    Lowenthal MN
    Trop Geogr Med; 1975 Jun; 27(2):132-6. PubMed ID: 1058559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
    Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.
    Gibbs JP; Murray G; Risler L; Chien JY; Dev R; Slattery JT
    Cancer Res; 1997 Dec; 57(24):5509-16. PubMed ID: 9407960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
    Ferrara F; Palmieri S; De Simone M; Sagristani M; Viola A; Pocali B; Fasanaro A; Mele G
    Br J Haematol; 2005 Jan; 128(2):234-41. PubMed ID: 15638859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of busulfan therapy in bone marrow transplantation. A nursing overview.
    Rohaly J
    Cancer Nurs; 1989 Jun; 12(3):144-52. PubMed ID: 2663138
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High dose busulfan and seizures.
    De La Camara R; Tomas JF; Figuera A; Berberana M; Fernandez-Rañada JM
    Bone Marrow Transplant; 1991 May; 7(5):363-4. PubMed ID: 2070145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The treatment of chronic leukemia in children].
    Koshel' IV
    Pediatriia; 1966 Oct; 45(10):15-8. PubMed ID: 5239925
    [No Abstract]   [Full Text] [Related]  

  • 54. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.
    Schultz KR; Ratanatharathorn V; Abella E; Eisenbrey AB; Karanes C; Lum LG; de Planque MM; Uberti JP; Ravindranath Y; Sensenbrenner LL
    Bone Marrow Transplant; 1994 Jun; 13(6):817-22. PubMed ID: 7920320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
    Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.
    Benadiba J; Ansari M; Krajinovic M; Vachon MF; Duval M; Teira P; Cellot S; Bittencourt H
    PLoS One; 2018; 13(4):e0193862. PubMed ID: 29608607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mannitol-busulphan in advanced ovary carcinoma.
    Cerný V; Sándor L; Winkler A; Ujházy V; Uhrínová M; Petrek C; Siracký J
    Neoplasma; 1966; 13(2):181-4. PubMed ID: 5950061
    [No Abstract]   [Full Text] [Related]  

  • 58. Platelet function after busulphan in chronic myeloproliferative disorders.
    Barbui T; Bassan R; Viero P; Cortelazzo S; Dini E
    Haematologica; 1983; 68(4):469-77. PubMed ID: 6414897
    [No Abstract]   [Full Text] [Related]  

  • 59. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung.
    Stott H; Stephens R; Fox W; Simon G; Roy DC
    Thorax; 1976 Jun; 31(3):265-70. PubMed ID: 781905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.